Bio & Pharma
MedPacto gets FDA OK for colorectal cancer drug clinical trial
It will carry out the Phase 2b/3 clinical trial to evaluate the efficacy of Vactosertib and Pembrolizumab combination therapy
By Jan 03, 2024 (Gmt+09:00)
1
Min read
Most Read
Hankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
NPS to hike risky asset purchases under simplified allocation system
Osstem to buy Brazil’s No. 3 dental implant maker Implacil
S.Korea's LS Materials set to boost earnings ahead of IPO process
UAE to invest up to $1 bn in S.Korean ventures
South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a combination therapy using Vactosertib and pembrolizumab (product name: Keytruda)
This trial will focus on patients previously undergoing metastatic colorectal cancer treatment.
It is a phase 2b/3 trial designed to assess the efficacy of the combination therapy with Vactosertib and Pembrolizumab.
The primary endpoint for this trial will be overall survival (OS). The trial is planned as a multi-national effort, including South Korea and the US locations.
MedPacto will conduct this trial with the support of Pembrolizumab provided free of charge by Merck (MSD), under a clinical trial collaboration and supply agreement.
Write to Yoo-Rim Kim at youforest@hankyung.com
This trial will focus on patients previously undergoing metastatic colorectal cancer treatment.
It is a phase 2b/3 trial designed to assess the efficacy of the combination therapy with Vactosertib and Pembrolizumab.
The primary endpoint for this trial will be overall survival (OS). The trial is planned as a multi-national effort, including South Korea and the US locations.
MedPacto will conduct this trial with the support of Pembrolizumab provided free of charge by Merck (MSD), under a clinical trial collaboration and supply agreement.
Write to Yoo-Rim Kim at youforest@hankyung.com
More to Read
-
Bio & PharmaMedPacto's anti-cancer substance designated as US FDA fast-track item
Jan 18, 2023 (Gmt+09:00)
1 Min read -
BiotechKorea’s MedPacto, Merck plan phase 3 trials of colorectal cancer drug
Dec 15, 2021 (Gmt+09:00)
2 Min read
Comment 0
LOG IN